(Q34250146)

31 July 2017

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients (English)

1 reference

31 July 2017

hepatocellular carcinoma

1 reference

T-S Yang

1

1 reference

31 July 2017

S-N Lu

2

1 reference

31 July 2017

Y Chao

3

1 reference

31 July 2017

I-S Sheen

4

1 reference

31 July 2017

C-C Lin

5

1 reference

31 July 2017

T-E Wang

6

1 reference

31 July 2017

S-C Chen

7

1 reference

31 July 2017

J-H Wang

8

1 reference

31 July 2017

L-Y Liao

9

1 reference

31 July 2017

J A Thomson

10

1 reference

31 July 2017

J Wang-Peng

11

1 reference

31 July 2017

P-J Chen

12

1 reference

31 July 2017

L-T Chen

13

1 reference

31 July 2017

language of work or name

English

0 references

publication date

31 August 2010

1 reference

British Journal of Cancer

31 July 2017

1 reference

31 July 2017

103

1 reference

31 July 2017

7

1 reference

31 July 2017

954-960

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605856

31 July 2017

0 references

cites work

Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

The impact of new data in the treatment of advanced hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Sorafenib in advanced hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Role of arginine metabolism in immunity and immunopathology

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Regulation of immune responses by L-arginine metabolism

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Updated treatment approach to hepatocellular carcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Hepatocellular carcinoma: systemic treatments

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Optimal two-stage designs for phase II clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation

6 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605856

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605856

Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605856

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605856

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605856

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605856

Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605856

Regression of hepatocellular cancer in a patient treated with arginine deiminase

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2965867

Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent

28 October 2018

1 reference

12 December 2020

Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma

1 reference

12 December 2020

Mammalian cell cultures contaminated with pleuropneumonia-like organisms. I. Effect of pleuropneumonia-like organisms on growth of established cell strains

1 reference

12 December 2020

Mycoplasma (PPLO) Strains with Lytic Activity for Murine Lymphoma Cells in vitro

1 reference

12 December 2020

MYCOPLASMA (PPLO) FROM COVERTLY CONTAMINATED TISSUE CULTURES: DIFFERENCES IN ARGININE DEGRADATION BETWEEN STRAINS

1 reference

12 December 2020

Growth response of stable and primary cell cultures to L-ornithine, L-citrulline, and L-arginine

1 reference

12 December 2020

Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan

1 reference

12 December 2020

Management of hepatocellular carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605856

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference